Article Text

Download PDFPDF
Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study
  1. G. Bolis*,
  2. S. Danese,
  3. S. Tateo,
  4. E. Rabaiotti§,
  5. G. D'Agostino,
  6. C. Merisio,
  7. G. Scarfone*,
  8. G. Polverino* and
  9. F. Parazzini*,#
  1. * Prima Clinica Ostetrico Ginecologica, Università di Milano, Milano, Italy
  2. Divisione di Ginecologia Oncologica, Osp. S. Anna di Torino, Torino, Italy
  3. Policlinico S. Matteo, Pavia, Italy
  4. § Clinica Ostetrico Ginecologica, Università di Milano, Osp. S. Raffaele, Milano, Italy
  5. Clinica Ostetrico Ginecologica, Università Cattolica Sacro Cuore, Roma, Italy
  6. Clinica Ostetrico Ginecologica, Università di Parma, Parma, Italy
  7. # Istituto di Ricerche Farmacologiche “Mario Negri”, Milano, Italy
  1. Address correspondence and reprint requests to: Fabio Parazzini, MD, Istituto di Ricerche Farmacologiche “Mario Negri”, Via Eritrea 62, 20157 Milano, Italy. Email: parazzini{at}


To compare the effect of epidoxorubicin given for 4 months versus no treatment in the survival of patients with advanced ovarian cancer and complete pathologic response after first-line surgery and chemotherapy with platinum-based schedules, we conducted a multicenter randomized clinical trial. Patients with histologic diagnosis of epithelial ovarian cancer FIGO stage III or IV at first diagnosis; complete pathologic response at second-look laparotomy/laparoscopy or complete clinic response; and those who have had first-line therapy including surgery and one regimen containing cisplatin or carboplatinum were eligible for the study and were randomly allocated to epidoxorubicin 120 mg/sqm or no treatment. A total of 64 women were allocated to epidoxorubicin and 74 to no treatment. There were 20 and 19 deaths, respectively, in the epidoxorubicin and no-treatment groups. The 3-year percent overall survival was 79.0% and 78.7%, respectively, in the no-treatment and epidoxorubicin groups (log-rank test, P= 0.93).

  • consolidation treatment
  • epidoxorubicin
  • ovarian cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.